Annual CFO
-$462.85 M
-$308.96 M-200.77%
September 30, 2024
Summary
- As of March 13, 2025, ARWR annual cash flow from operations is -$462.85 million, with the most recent change of -$308.96 million (-200.77%) on September 30, 2024.
- During the last 3 years, ARWR annual CFO has fallen by -$634.16 million (-370.18%).
- ARWR annual CFO is now -367.49% below its all-time high of $173.03 million, reached on September 30, 2019.
Performance
ARWR Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$146.27 M
-$9.06 M-6.60%
December 31, 2024
Summary
- As of March 13, 2025, ARWR quarterly cash flow from operations is -$146.27 million, with the most recent change of -$9.06 million (-6.60%) on December 31, 2024.
- Over the past year, ARWR quarterly CFO has dropped by -$9.06 million (-6.60%).
- ARWR quarterly CFO is now -155.43% below its all-time high of $263.87 million, reached on March 31, 2021.
Performance
ARWR Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$491.28 M
-$28.43 M-6.14%
December 31, 2024
Summary
- As of March 13, 2025, ARWR TTM cash flow from operations is -$491.28 million, with the most recent change of -$28.43 million (-6.14%) on December 31, 2024.
- Over the past year, ARWR TTM CFO has dropped by -$28.43 million (-6.14%).
- ARWR TTM CFO is now -366.88% below its all-time high of $184.08 million, reached on June 30, 2021.
Performance
ARWR TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ARWR Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -200.8% | -6.6% | -6.1% |
| 3 y3 years | -370.2% | -6.6% | -6.1% |
| 5 y5 years | -367.5% | -6.6% | -6.1% |
ARWR Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -370.2% | at low | -333.2% | at low | -429.9% | at low |
| 5 y | 5-year | -367.5% | at low | -155.4% | at low | -366.9% | at low |
| alltime | all time | -367.5% | at low | -155.4% | at low | -366.9% | at low |
Arrowhead Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$146.27 M(+6.6%) | -$491.28 M(+6.1%) |
| Sep 2024 | -$462.85 M(+200.8%) | -$137.22 M(+18.9%) | -$462.85 M(+31.7%) |
| Jun 2024 | - | -$115.42 M(+24.9%) | -$351.56 M(+36.8%) |
| Mar 2024 | - | -$92.38 M(-21.6%) | -$256.92 M(+30.9%) |
| Dec 2023 | - | -$117.84 M(+354.5%) | -$196.21 M(+27.5%) |
| Sep 2023 | -$153.89 M(+13.0%) | -$25.93 M(+24.8%) | -$153.89 M(-21.8%) |
| Jun 2023 | - | -$20.78 M(-34.4%) | -$196.70 M(-19.6%) |
| Mar 2023 | - | -$31.67 M(-58.1%) | -$244.74 M(+62.8%) |
| Dec 2022 | - | -$75.52 M(+9.9%) | -$150.34 M(+10.4%) |
| Sep 2022 | -$136.13 M(-179.5%) | -$68.74 M(-0.1%) | -$136.13 M(+48.9%) |
| Jun 2022 | - | -$68.81 M(-209.7%) | -$91.42 M(+75.1%) |
| Mar 2022 | - | $62.73 M(-202.3%) | -$52.22 M(-135.1%) |
| Dec 2021 | - | -$61.31 M(+155.1%) | $148.93 M(-13.1%) |
| Sep 2021 | $171.31 M(-278.8%) | -$24.03 M(-18.8%) | $171.31 M(-6.9%) |
| Jun 2021 | - | -$29.61 M(-111.2%) | $184.08 M(+2.1%) |
| Mar 2021 | - | $263.87 M(-778.0%) | $180.26 M(-262.1%) |
| Dec 2020 | - | -$38.92 M(+245.7%) | -$111.19 M(+16.1%) |
| Sep 2020 | -$95.80 M(-155.4%) | -$11.26 M(-66.3%) | -$95.80 M(+35.4%) |
| Jun 2020 | - | -$33.43 M(+21.2%) | -$70.73 M(+164.1%) |
| Mar 2020 | - | -$27.59 M(+17.2%) | -$26.78 M(+42.6%) |
| Dec 2019 | - | -$23.53 M(-270.4%) | -$18.78 M(-110.9%) |
| Sep 2019 | $173.03 M(-466.4%) | $13.81 M(+31.2%) | $173.04 M(+10.5%) |
| Jun 2019 | - | $10.53 M(-153.7%) | $156.54 M(+18.9%) |
| Mar 2019 | - | -$19.59 M(-111.6%) | $131.61 M(-3.1%) |
| Dec 2018 | - | $168.28 M(-6378.6%) | $135.75 M(-387.5%) |
| Sep 2018 | -$47.22 M(+97.3%) | -$2.68 M(-81.4%) | -$47.22 M(-12.1%) |
| Jun 2018 | - | -$14.41 M(-6.7%) | -$53.75 M(+8.0%) |
| Mar 2018 | - | -$15.44 M(+5.1%) | -$49.75 M(+2.3%) |
| Dec 2017 | - | -$14.69 M(+59.6%) | -$48.63 M(+103.1%) |
| Sep 2017 | -$23.94 M(-62.8%) | -$9.20 M(-11.6%) | -$23.94 M(-3.9%) |
| Jun 2017 | - | -$10.41 M(-27.3%) | -$24.92 M(-24.2%) |
| Mar 2017 | - | -$14.33 M(-243.3%) | -$32.86 M(-1.3%) |
| Dec 2016 | - | $10.00 M(-198.2%) | -$33.28 M(-48.3%) |
| Sep 2016 | -$64.43 M(-1.9%) | -$10.18 M(-44.5%) | -$64.43 M(-2.8%) |
| Jun 2016 | - | -$18.35 M(+24.4%) | -$66.27 M(+8.6%) |
| Mar 2016 | - | -$14.75 M(-30.3%) | -$61.03 M(-2.6%) |
| Dec 2015 | - | -$21.15 M(+75.9%) | -$62.66 M(-4.6%) |
| Sep 2015 | -$65.71 M(+85.5%) | -$12.02 M(-8.4%) | -$65.71 M(+1.7%) |
| Jun 2015 | - | -$13.12 M(-19.9%) | -$64.61 M(+5.5%) |
| Mar 2015 | - | -$16.37 M(-32.4%) | -$61.27 M(+16.5%) |
| Dec 2014 | - | -$24.20 M(+121.6%) | -$52.59 M(+48.5%) |
| Sep 2014 | -$35.42 M(+86.1%) | -$10.92 M(+11.7%) | -$35.42 M(+18.5%) |
| Jun 2014 | - | -$9.78 M(+27.0%) | -$29.89 M(+17.5%) |
| Mar 2014 | - | -$7.70 M(+9.6%) | -$25.45 M(+14.5%) |
| Dec 2013 | - | -$7.02 M(+30.2%) | -$22.22 M(+16.7%) |
| Sep 2013 | -$19.03 M(+24.1%) | -$5.39 M(+1.1%) | -$19.03 M(+4.4%) |
| Jun 2013 | - | -$5.33 M(+19.4%) | -$18.23 M(+8.6%) |
| Mar 2013 | - | -$4.47 M(+16.4%) | -$16.78 M(+1.9%) |
| Dec 2012 | - | -$3.84 M(-16.4%) | -$16.47 M(+7.4%) |
| Sep 2012 | -$15.34 M | -$4.59 M(+18.0%) | -$15.34 M(+23.6%) |
| Jun 2012 | - | -$3.89 M(-6.5%) | -$12.42 M(+30.0%) |
| Mar 2012 | - | -$4.16 M(+53.7%) | -$9.55 M(+43.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | -$2.71 M(+62.7%) | -$6.67 M(+23.8%) |
| Sep 2011 | -$5.39 M(-30.0%) | -$1.66 M(+62.4%) | -$5.39 M(-13.6%) |
| Jun 2011 | - | -$1.02 M(-20.0%) | -$6.24 M(-10.8%) |
| Mar 2011 | - | -$1.28 M(-10.1%) | -$6.99 M(-6.6%) |
| Dec 2010 | - | -$1.42 M(-43.3%) | -$7.49 M(-2.7%) |
| Sep 2010 | -$7.70 M(-49.6%) | -$2.51 M(+41.3%) | -$7.70 M(+1.3%) |
| Jun 2010 | - | -$1.78 M(+0.2%) | -$7.60 M(+4.0%) |
| Mar 2010 | - | -$1.77 M(+8.6%) | -$7.31 M(-28.4%) |
| Dec 2009 | - | -$1.63 M(-32.4%) | -$10.21 M(-33.2%) |
| Sep 2009 | -$15.28 M(-44.6%) | -$2.42 M(+62.8%) | -$15.28 M(-28.1%) |
| Jun 2009 | - | -$1.48 M(-68.3%) | -$21.25 M(-22.5%) |
| Mar 2009 | - | -$4.68 M(-30.1%) | -$27.42 M(-3.6%) |
| Dec 2008 | - | -$6.70 M(-20.1%) | -$28.45 M(+3.1%) |
| Sep 2008 | -$27.58 M(+15.6%) | -$8.38 M(+9.5%) | -$27.58 M(+7.3%) |
| Jun 2008 | - | -$7.65 M(+34.0%) | -$25.70 M(+8.5%) |
| Mar 2008 | - | -$5.71 M(-2.0%) | -$23.68 M(-3.8%) |
| Dec 2007 | - | -$5.83 M(-10.2%) | -$24.61 M(+3.1%) |
| Sep 2007 | -$23.87 M(+61.4%) | -$6.50 M(+15.3%) | -$23.87 M(+13.5%) |
| Jun 2007 | - | -$5.64 M(-15.1%) | -$21.03 M(+5.7%) |
| Mar 2007 | - | -$6.64 M(+30.5%) | -$19.90 M(+19.2%) |
| Dec 2006 | - | -$5.09 M(+38.9%) | -$16.69 M(+12.9%) |
| Sep 2006 | -$14.79 M(+62.6%) | -$3.66 M(-18.7%) | -$14.79 M(+7.9%) |
| Jun 2006 | - | -$4.51 M(+31.3%) | -$13.71 M(+13.0%) |
| Mar 2006 | - | -$3.43 M(+7.6%) | -$12.14 M(+17.4%) |
| Dec 2005 | - | -$3.19 M(+23.3%) | -$10.34 M(+13.7%) |
| Sep 2005 | -$9.10 M(+293.2%) | -$2.59 M(-11.9%) | -$9.10 M(+26.1%) |
| Jun 2005 | - | -$2.93 M(+79.6%) | -$7.21 M(+41.6%) |
| Mar 2005 | - | -$1.63 M(-16.1%) | -$5.09 M(+29.3%) |
| Dec 2004 | - | -$1.95 M(+178.0%) | -$3.94 M(+70.2%) |
| Sep 2004 | -$2.31 M(+1368.5%) | -$700.00 K(-14.2%) | -$2.31 M(+35.3%) |
| Jun 2004 | - | -$815.40 K(+70.3%) | -$1.71 M(+89.5%) |
| Mar 2004 | - | -$478.80 K(+49.5%) | -$902.80 K(+95.5%) |
| Dec 2003 | - | -$320.20 K(+232.5%) | -$461.90 K(+193.1%) |
| Sep 2003 | -$157.60 K(+49.0%) | -$96.30 K(+1184.0%) | -$157.60 K(+109.0%) |
| Jun 2003 | - | -$7500.00(-80.2%) | -$75.40 K(-35.5%) |
| Mar 2003 | - | -$37.90 K(+138.4%) | -$116.90 K(+23.2%) |
| Dec 2002 | - | -$15.90 K(+12.8%) | -$94.90 K(-10.4%) |
| Sep 2002 | -$105.80 K(+29.3%) | -$14.10 K(-71.2%) | -$105.90 K(-0.6%) |
| Jun 2002 | - | -$49.00 K(+208.2%) | -$106.50 K(+46.1%) |
| Mar 2002 | - | -$15.90 K(-40.9%) | -$72.90 K(-18.9%) |
| Dec 2001 | - | -$26.90 K(+83.0%) | -$89.90 K(+9.8%) |
| Sep 2001 | -$81.80 K(+2.1%) | -$14.70 K(-4.5%) | -$81.90 K(-7.2%) |
| Jun 2001 | - | -$15.40 K(-53.2%) | -$88.30 K(-34.3%) |
| Mar 2001 | - | -$32.90 K(+74.1%) | -$134.30 K(+33.9%) |
| Dec 2000 | - | -$18.90 K(-10.4%) | -$100.30 K(+25.1%) |
| Sep 2000 | -$80.10 K(+127.6%) | -$21.10 K(-65.6%) | -$80.20 K(+35.7%) |
| Jun 2000 | - | -$61.40 K(-5681.8%) | -$59.10 K(-2669.6%) |
| Mar 2000 | - | $1100.00(-8.3%) | $2300.00(+91.7%) |
| Dec 1999 | - | $1200.00 | $1200.00 |
| Sep 1999 | -$35.20 K(<-9900.0%) | - | - |
| Sep 1998 | $100.00(-97.8%) | - | - |
| Sep 1997 | $4600.00 | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual CFO year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly CFO year-on-year change?
- What is Arrowhead Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM CFO year-on-year change?
What is Arrowhead Pharmaceuticals annual cash flow from operations?
The current annual CFO of ARWR is -$462.85 M
What is the all time high annual CFO for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual cash flow from operations is $173.03 M
What is Arrowhead Pharmaceuticals annual CFO year-on-year change?
Over the past year, ARWR annual cash flow from operations has changed by -$308.96 M (-200.77%)
What is Arrowhead Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ARWR is -$146.27 M
What is the all time high quarterly CFO for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly cash flow from operations is $263.87 M
What is Arrowhead Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ARWR quarterly cash flow from operations has changed by -$9.06 M (-6.60%)
What is Arrowhead Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ARWR is -$491.28 M
What is the all time high TTM CFO for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM cash flow from operations is $184.08 M
What is Arrowhead Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ARWR TTM cash flow from operations has changed by -$28.43 M (-6.14%)